Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7035842 | 1.00 | SMN1; SMN2 (0.38) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL3704585 | 1.00 | SMN1; SMN2 (0.38) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL6437019 | 0.98 | LMNA (0.40) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL28870771 | 0.93 | — | — | |
| SCHEMBL6440601 | 0.86 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL6433662 | 0.84 | ALDH1A1 (0.52) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL7708022 | 0.84 | ALDH1A1 (0.59) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL11443981 | 0.84 | ALDH1A1 (0.52) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL6435404 | 0.84 | ALDH1A1 (0.52) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL10911265 | 0.84 | ALDH1A1 (0.59) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365183-B2 | Eicosanoid derivatives | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2022-06-21 | — | — | US | disclosed |
| US-20190315701-A1 | NOVEL EICOSANOID DERIVATIVES | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2019-10-17 | — | — | US | disclosed |
| US-10287262-B2 | Eicosanoid derivatives | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2019-05-14 | — | — | US | disclosed |
| EP-3222612-A1 | NOVEL EICOSANOID DERIVATIVES | Max-Delbrück-Centrum für Molekulare Medizin (MDC) (DE) | 2017-09-27 | — | — | EP | disclosed |
| EP-2376432-B1 | NOVEL EICOSANOID DERIVATIVES | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (MDC) (DE) | 2017-04-12 | — | — | EP | disclosed |
| US-20160326128-A1 | NOVEL EICOSANOID DERIVATIVES | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2016-11-10 | — | — | US | disclosed |
| US-20160326128-A1 | NOVEL EICOSANOID DERIVATIVES | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2016-11-10 | — | — | US | disclosed |
| US-9272991-B2 | Eicosanoid derivatives | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (MDC) (DE) | 2016-03-01 | — | — | US | disclosed |
| US-9272991-B2 | Eicosanoid derivatives | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (MDC) (DE) | 2016-03-01 | — | — | US | disclosed |
| US-20120122972-A1 | NOVEL EICOSANOID DERIVATIVES | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (MDC) (DE) | 2012-05-17 | — | — | US | disclosed |
| US-20120122972-A1 | NOVEL EICOSANOID DERIVATIVES | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (MDC) (DE) | 2012-05-17 | — | — | US | disclosed |
| EP-2208720-A1 | Novel eicosanoid derivatives | Max-Delbrück-Centrum für Molekulare Medizin (MDC) (DE) | 2010-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122972-A1 | NOVEL EICOSANOID DERIVATIVES | FABP3, PTGER3, PTGES3 | SMN1; SMN2 3024/4885LMNA 741/4885ALDH1A1 646/4885 |
| US-10287262-B2 | Eicosanoid derivatives | FABP3, PTGER3, PTGES3 | SMN1; SMN2 3031/4885LMNA 722/4885ALDH1A1 708/4885 |
| US-11365183-B2 | Eicosanoid derivatives | FABP3, PTGER3, PTGES3 | SMN1; SMN2 3031/4885LMNA 722/4885ALDH1A1 708/4885 |
| US-20160326128-A1 | NOVEL EICOSANOID DERIVATIVES | FABP3, PTGER3, PTGES3 | SMN1; SMN2 2904/4885LMNA 730/4885ALDH1A1 710/4885 |
| US-20190315701-A1 | NOVEL EICOSANOID DERIVATIVES | FABP3, PTGER3, PTGES3 | SMN1; SMN2 2904/4885LMNA 730/4885ALDH1A1 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.